Physician profile
Amal Shine
NPI 1043744329
$7,184.12
in general payments reported to CMS, 2019-2025
18 companies · $708 in 2025
The $708 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $114 · 2021: $923 · 2022: $2,208 · 2023: $1,279 · 2024: $1,830 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,958 · Travel and Lodging: $1,859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,958.28 |
| Travel and Lodging | $1,859.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,896.52 | 2020-2025 | Resolution 360 Clip, Spyglass, Captivator II |
| Abbvie INC. | $898.65 | 2019-2025 | |
| Olympus Corporation of The Americas | $790.25 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $722.27 | 2021-2022 | |
| Micro-Tech Endoscopy USA, INC. | $291.29 | 2024-2025 | Lesionhunter |
| E.R. Squibb & Sons, L.L.C. | $249.27 | 2021-2022 | |
| Medtronic, INC. | $223.55 | 2022-2024 | Nexpowder, Endoflip |
| Takeda Pharmaceuticals U.S.A., INC. | $208.89 | 2022 | |
| Enterra Medical, INC. | $175.57 | 2025 | |
| Mallinckrodt Hospital Products INC. | $154.55 | 2022-2024 | Terlivaz |
| Erbe USA INC | $127.50 | 2024 | Vio3 Apc3 |
| Eisai INC. | $124.74 | 2022 | |
| Alexion Pharmaceuticals, INC. | $105.40 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $85.00 | 2024 | |
| Janssen Biotech, INC. | $38.83 | 2025 | Tremfya |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $36.30 | 2024 | Iqirvo |
| Olympus America INC. | $34.83 | 2025 | Gastrointestinal Videoscope, Evis Exera III Colonovideoscope |
| Exelixis INC. | $20.71 | 2025 | Cabometyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amal Shine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.